Holen Sie sich die Stockscreener-App
35.25
1.15%
-0.41
Schlusskurs vom Vortag:
$35.66
Offen:
$35.36
24-Stunden-Volumen:
483.51K
Relative Volume:
1.02
Marktkapitalisierung:
$2.47B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-11.10
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
-0.20%
1M Leistung:
+4.07%
6M Leistung:
+31.53%
1J Leistung:
+60.37%
1-Tages-Spanne:
$35.21
$36.39
1-Wochen-Bereich:
$33.80
$36.39
52-Wochen-Spanne:
$20.65
$38.13
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
35.25 | 2.55B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighWhat's Next? - MarketBeat
Foresite Capital Management V, LLC's Pharvaris NV(PHVS) Holding History - GuruFocus
Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares - MarketBeat
Pharvaris (PHVS) CEO sells 2,292 shares after RSU vesting - Stock Titan
What is HC Wainwright's Forecast for Pharvaris Q3 Earnings? - MarketBeat
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Research Analysts Issue Forecasts for Pharvaris Q4 Earnings - MarketBeat
General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership - Stock Titan
PHVS (NASDAQ: PHVS) holder Berndt Modig plans 2,292-share stock sale - Stock Titan
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress - Investing.com
Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions - Kalkine Media
PHVS Maintains Outperform Rating -- Price Target Raised to $52.0 - GuruFocus
Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says - marketscreener.com
PHVS Maintains Rating by Citizens -- Price Target Raised to $75. - GuruFocus
RBC Adjusts PT on Pharvaris to $52 From $51, Maintains Outperform Speculative Risk Rating - marketscreener.com
Citizens raises Pharvaris stock price target to $75 on trial progress - Investing.com Australia
Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Pharvaris Q2 EPS of $(0.81) misses $(0.74) analyst estimate - scanx.trade
Pharvaris N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
(PHVS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones - TipRanks
Pharvaris' Q2 Loss Per Share Narrows - marketscreener.com
Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share - marketscreener.com
Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position - Quiver Quantitative
Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date - Stock Titan
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update - Enidnews.com
Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can Pharvaris (PHVS) Turn AAE-C1INH Patient Insights Into a Lasting Clinical Advantage? - Sahm
Claude AI's Latest Portfolio Additions Spotlight Pharvaris and Micron as Hedge Fund FavoritesROIC Trend Report - dars.gov.et
Pharvaris NV (PHVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Pharvaris (NASDAQ:PHVS) Sets New 12-Month HighWhat's Next? - MarketBeat
Pharvaris N.V. (PHVS) Stock Analysis: Unpacking a 40% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris NV (PHVS) Stock News Today - TradingKey
Pharvaris publishes study on rare angioedema condition By Investing.com - Investing.com South Africa
Pharvaris publishes study on rare angioedema condition - Investing.com
Painful swelling and misdiagnoses disrupted daily life in Pharvaris study - Stock Titan
Pharvaris (PHVS) Rallies 5.63% to $35.30 as Momentum Builds Toward Key ResistanceETF AUM Growth - vinanet.vn
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment (NASDAQ:PHVS) - Seeking Alpha
Pharvaris (PHVS) Climbs 5% as Momentum Builds Toward $35.56 ResistanceIron Condor Alert - dars.gov.et
Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run - Yahoo Finance
DV Trading LLC Invests $4.07 Million in Pharvaris N.V. $PHVS - MarketBeat
(PHVS) Risk Channels and Responsive Allocation - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Analysis: A Biotech With 41.23% Potential Upside - DirectorsTalk Interviews
Pharvaris N.V. (PHVS) investor LSP V trims stake to 4.9% of shares - Stock Titan
Pharvaris N.V. $PHVS Shares Sold by Eversept Partners LP - MarketBeat
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):